Ibezapolstat is under clinical development by Acurx Pharmaceuticals and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ibezapolstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibezapolstat overview
Ibezapolstat (ACX-362E) is under development for the treatment of Clostridium difficile Infections. The drug candidate is administered through oral route in the form of capsules. It acts by targeting DNA polymerase IIIc. Th drug candidate is an analog of 2-deoxyguanosine 5-triphosphate (dGTP).
Acurx Pharmaceuticals overview
Acurx Pharmaceuticals, LLC, (formerly Ampex Pharmaceuticals), a biopharmaceutical company that focused on developing new antibiotics for difficult to treat infections. The company is headquartered in United States.
For a complete picture of Ibezapolstat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.